Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...

ILUVIEN revenues should pick up by the end of the year. DME is a chronic disease and there is a desperate need for a sustained release treatment and ILUVIEN fills that need very well.

This note focuses on the implications of the complete response letter (( CRL)) received by Alimera ( ALIM) for Iluvien. This product was developed by pSivida ( PSDV) but was partnered with Alimera ...

A single ILUVIEN implant significantly delayed recurrence and reduced uveitis symptoms upon recurrence compared to active control arm Recently approved in Europe, ILUVIEN is expected to launch in ...

Iluvien was approved by the Food and Drug Administration back in 2014 for the treatment of DME in patients who were previously treated with corticosteroids without a clinically significant rise in ...

ATLANTA, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the ...

pSivida announced that its partner Alimera Sciences has successfully conducted labeling discussions with the FDA for Iluvien for the treatment of Diabetic Macular Edema.

--Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that INFARMED, the ...